Hope Medicine's HMI-115 Receives FDA Fast Track Designation for Endometriosis Pain Treatment
Key Insights
Hope Medicine's HMI-115, a monoclonal antibody targeting the prolactin receptor (search), received FDA Fast Track Designation for treating moderate to severe endometriosis (search)-associated pain.
Phase II clinical trial results showed HMI-115 reduced dysmenorrhea (search) pain scores by 42% and non-menstrual chronic pelvic pain (search) scores by 52% without affecting menstrual cycles or hormone levels.
The designation follows previous Breakthrough Therapy Designation from China's NMPA and aims to accelerate development for a condition affecting approximately 190 million women worldwide.
Hope Medicine Inc. (search) announced that its lead pipeline product HMI-115, a monoclonal antibody targeting the prolactin receptor (search), has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of moderate to severe pain associated with endometriosis (search). The designation marks a significant milestone in the global development of HMI-115, building on its previous inclusion in China's National Medical Products Administration Breakthrough Therapy Designation list.
Clinical Trial Results Drive FDA Decision
The FDA Fast Track Designation was based on results from a completed global Phase II clinical trial that demonstrated HMI-115's efficacy and safety profile. The international, multicenter, randomized, double-blind, placebo-controlled dose-finding study evaluated HMI-115 in 108 female patients with surgically diagnosed endometriosis (search) across the United States, Poland, and China over a 12-week treatment period.
The trial results showed statistically significant improvements in endometriosis (search)-associated pain. At the end of treatment, the least-square-mean dysmenorrhea (search) pain score in the 240 mg every two weeks dose group decreased by 42% from baseline, while the non-menstrual chronic pelvic pain (search) score decreased by 52%, both with statistical significance. The drug was well-tolerated overall, with no drug-related serious adverse events reported.
Favorable Safety Profile
A key differentiator for HMI-115 was its ability to provide pain relief while maintaining normal physiological function. Most patients maintained normal menstrual cycles throughout the treatment period, and no typical peri-menopausal symptoms were reported. Additionally, there were no significant changes in bone mineral density or levels of sex hormones including estradiol, luteinizing hormone, follicle-stimulating hormone, and progesterone.
The results of this proof-of-concept global Phase II clinical trial have been formally published in The Lancet Obstetrics, Gynaecology & Women's Health, providing peer-reviewed validation of the findings.
Addressing Significant Unmet Medical Need
Endometriosis (search) affects approximately 10% of women of reproductive age globally, equating to about 190 million women worldwide. The condition is characterized by the implantation of endometrial cells outside the uterine cavity, typically presenting as a chronic inflammatory response. Symptoms include lower abdominal and pelvic pain, dysmenorrhea (search), painful intercourse, and infertility (search).
The disease burden is substantial, with 20%-50% of women with infertility (search) having endometriosis (search), and 71%-87% of women with chronic pelvic pain (search) having the condition. Endometriosis often leads to decreased quality of life, affecting patients' sexual health, psychological well-being, and social behavior. The global market for endometriosis treatments represents a potential size of approximately $200 billion, according to a McKinsey report.
Regulatory Pathway and Development Timeline
The FDA Fast Track Designation is a special program designed to facilitate development and expedite review of drugs intended to treat serious conditions with unmet medical needs. Drug candidates granted this designation qualify for more frequent interactions and timely feedback from the FDA during subsequent development and review processes.
As a potential first-in-class global treatment for endometriosis (search), the FDA Fast Track Designation for HMI-115 is expected to accelerate its development, review, and approval process, potentially bringing the treatment to patients worldwide sooner. The designation complements the company's previous regulatory success with China's NMPA, positioning HMI-115 for global development across major pharmaceutical markets.